If Cramer says to sell something it's usually the best time to buy. Cramer is great at reminding viewers when he's right but is quiet when he's wrong. Which is OFTEN!
The deal between the US and Iran is the least of the problems in that area IMO. The first time we hear about oil tankers being blocked or shot at oil will go through the roof. Demand or not!
Who knows where oil could open Monday. It's a lot more than just talks with Iran. It's Yemen,Egypt, Iraq, Israel. the whole thing could erupt at any time. That's something the charts can't tell you.
And this is coming from the guy that predicted the stock would close at $25 for 2 weeks in a row. Now he is trying to find reasons why it didn't drop. It didn't drop because it's a great stock that's going MUCH higher in the months ahead. You were wrong because you shorted it and are getting more desperate by the day. At least people are having fun laughing at you.
The ask has been at $4 until about 15 min. ago. They know what they have and aren't willing to sell cheap.
4:11 pm EDAP TMS SA announces its participation in a major collaborative liver cancer project aimed at developing innovative new therapies for this prevalent indication (EDAP) : HEpatocellular CArcinoma Multi-technological is a 5-year, 41.0 million project. 18.2 million of the financing is provided by Bpifrance to companies to facilitate the development of their industrial projects. EDAP's focus within the HECAM consortium is on developing a novel HIFU treatment for liver cancer in cooperation with its long-term academic partner INSERM and leading cancer centers. To fund this development program, EDAP will receive 2.4 million in non-dilutive financing from Bpifrance over the 5 year project period.
U.S health regulators on Wednesday expanded the approved use for Eylea, Regeneron Pharmaceuticals Inc.'s (RGEN) vision drug, to treat the most common eye disease affecting patients with a type of retina swelling known as diabetic macular edema.